These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26120082)

  • 21. Tumor suppressor Menin acts as a corepressor of LXRα to inhibit hepatic lipogenesis.
    Cheng P; Li G; Yang SS; Liu R; Jin G; Zhou XY; Hu XG
    FEBS Lett; 2015 Oct; 589(20 Pt B):3079-84. PubMed ID: 25962847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective Killing of Cancer Cells Through ROS-Mediated Mechanisms by AMRI-59 Targeting Peroxiredoxin I.
    Yang YJ; Baek JY; Goo J; Shin Y; Park JK; Jang JY; Wang SB; Jeong W; Lee HJ; Um HD; Lee SK; Choi Y; Rhee SG; Chang TS
    Antioxid Redox Signal; 2016 Mar; 24(8):453-69. PubMed ID: 26528922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and optimization of a series of liver X receptor antagonists.
    Jiao X; Kopecky DJ; Fisher B; Piper DE; Labelle M; McKendry S; Harrison M; Jones S; Jaen J; Shiau AK; Escaron P; Danao J; Chai A; Coward P; Kayser F
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5966-70. PubMed ID: 22901900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis.
    Ma J; Duan W; Han S; Lei J; Xu Q; Chen X; Jiang Z; Nan L; Li J; Chen K; Han L; Wang Z; Li X; Wu E; Huo X
    Oncotarget; 2015 Aug; 6(25):20993-1003. PubMed ID: 25895130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and structure activity relationship of the first class of LXR inverse agonists.
    Elgendy B; Griffett K; Hegazy L; Di Fruscia P; Sample K; Schoepke E; Kamenecka TM; Burris TP
    Bioorg Chem; 2022 Feb; 119():105540. PubMed ID: 34902646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells.
    Hoang MH; Jia Y; Jun HJ; Lee JH; Lee DH; Hwang BY; Kim WJ; Lee HJ; Lee SJ
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4094-9. PubMed ID: 22579484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux.
    Hessvik NP; Boekschoten MV; Baltzersen MA; Kersten S; Xu X; Andersén H; Rustan AC; Thoresen GH
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E602-13. PubMed ID: 19996385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice.
    Lo Sasso G; Bovenga F; Murzilli S; Salvatore L; Di Tullio G; Martelli N; D'Orazio A; Rainaldi S; Vacca M; Mangia A; Palasciano G; Moschetta A
    Gastroenterology; 2013 Jun; 144(7):1497-507, 1507.e1-13. PubMed ID: 23419360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of aerobic glycolysis to decelerate tumor proliferation by small molecule inhibitors targeting glucose transporters.
    Gao M; Huang J; Jiang X; Yuan Y; Pang H; Luo S; Wang N; Yao C; Lin Z; Pu D; Zhang S; Sun P; Liu Z; Xiao Y; Wang Q; Hu Z; Yin H
    Protein Cell; 2020 Jun; 11(6):446-451. PubMed ID: 32410006
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemical genetics in tumor lipogenesis.
    Braig S
    Biotechnol Adv; 2018 Nov; 36(6):1724-1729. PubMed ID: 29447918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.
    Wegiel B; Gallo D; Csizmadia E; Harris C; Belcher J; Vercellotti GM; Penacho N; Seth P; Sukhatme V; Ahmed A; Pandolfi PP; Helczynski L; Bjartell A; Persson JL; Otterbein LE
    Cancer Res; 2013 Dec; 73(23):7009-21. PubMed ID: 24121491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial: anti-lipogenesis as a novel strategy for cancer therapy.
    Liu J; Cao D
    Recent Pat Anticancer Drug Discov; 2012 May; 7(2):149-53. PubMed ID: 22338611
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.
    Griffett K; Burris TP
    Front Med (Lausanne); 2023; 10():1102469. PubMed ID: 36817797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are Synthetic Compounds that Silence the Liver-X-Receptor the Next Generation of Anti-cancer Drugs?
    Steffensen KR
    Cancer Cell; 2015 Jul; 28(1):3-4. PubMed ID: 26175408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticancer drugs: Repressing LXRs to starve cancer.
    Kingwell K
    Nat Rev Drug Discov; 2015 Sep; 14(9):602. PubMed ID: 26323542
    [No Abstract]   [Full Text] [Related]  

  • 36. 2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.
    Wang SY; Wei YH; Shieh DB; Lin LL; Cheng SP; Wang PW; Chuang JH
    PLoS One; 2015; 10(7):e0130959. PubMed ID: 26134286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs.
    Hsu CC; Wu LC; Hsia CY; Yin PH; Chi CW; Yeh TS; Lee HC
    Oncol Rep; 2015 Sep; 34(3):1620-8. PubMed ID: 26133123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.
    Villa GR; Hulce JJ; Zanca C; Bi J; Ikegami S; Cahill GL; Gu Y; Lum KM; Masui K; Yang H; Rong X; Hong C; Turner KM; Liu F; Hon GC; Jenkins D; Martini M; Armando AM; Quehenberger O; Cloughesy TF; Furnari FB; Cavenee WK; Tontonoz P; Gahman TC; Shiau AK; Cravatt BF; Mischel PS
    Cancer Cell; 2016 Nov; 30(5):683-693. PubMed ID: 27746144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC Is a Major Determinant of Mitotic Cell Fate.
    Topham C; Tighe A; Ly P; Bennett A; Sloss O; Nelson L; Ridgway RA; Huels D; Littler S; Schandl C; Sun Y; Bechi B; Procter DJ; Sansom OJ; Cleveland DW; Taylor SS
    Cancer Cell; 2015 Jul; 28(1):129-40. PubMed ID: 26175417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.
    Lee HO; Mustafa A; Hudes GR; Kruger WD
    PLoS One; 2015; 10(7):e0131464. PubMed ID: 26134285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.